STAT

87 experimental therapies for glioblastoma are in the works. Some might help McCain now

Recent advances have scientists thinking that effective treatments are on the horizon for glioblastoma — and some might help Sen. John McCain.
Sen. John McCain talks to reporters at the Capitol in February.

Glioblastoma, the brain cancer that Sen. John McCain has, is invariably — and accurately — described as aggressive and as having a poor prognosis: Not even Sen. Edward Kennedy or Beau Biden, with access to the best care and most cutting-edge therapies in the world, beat it. Recent advances, however, have persuaded some scientists that effective treatments are on the horizon — and some might even help McCain live longer than earlier patients did. 

“We’ve learned a tremendous amount about the biology of this cancer,” said Dr. David Reardon, director of neuro-oncology at Boston’s Dana-Farber Cancer Institute. That includes understanding “the mutations and other abnormalities that give tumors an advantage, how they adapt and become resistant [to chemotherapy], and how to get treatments across the blood-brain barrier” that is notorious for keeping out drugs.

As a result, he said, “there are an increasing number of drugs that are making their way toward the clinic.”

Market research company Informa

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks